Document:

Exhibit 10.5

 

EXECUTION COPY

 

 

University of Pennsylvania

 

Third Amendment to the Amended and Restated
Patent License Agreement

 

This Third Amendment
(the “Third Amendment”) is made and entered into as of December 12, 2011 (the “Effective Date”) by and
between The Trustees of the University of Pennsylvania (hereinafter referred to as “Penn”) and Advaxis, Inc., a corporation
organized and existing under the laws of Delaware (hereinafter referred to as “Company”) having a place of business
at 305 College Road East, Princeton, NJ 08540.

 

WHEREAS, Penn and Company
entered into an Amended and Restated License Agreement dated February 13, 2007 (the “Agreement”); and

 

WHEREAS, Penn and Company
entered into a First Amendment to the Agreement dated March 26, 2007 (the “First Amendment”); and

 

WHEREAS, Penn and Company
entered into a Second Amendment to the Agreement dated May 10, 2010 (the “Second Amendment”); and

 

WHEREAS, Company desires
to further amend the Agreement to add docket numbers W5279 and X5631 (hereinafter referred to as the “Additional Penn Dockets”)
developed under the supervision of, or in collaboration with, Dr. Yvonne Paterson;

 

All terms not specifically
defined herein will have the meaning ascribed to them in the Agreement, as amended.

 

Now, therefore, in
consideration of the foregoing premises, and intending to be legally bound hereby, the parties hereto agree as follows:

 

		1)	Attachment 1 - List of Intellectual Property is deleted in its entirety and replaced with Exhibit 1
to this Third Amendment, which includes the Additional Penn Dockets.

 

		2)	On the Effective Date of this Third Amendment Company shall pay to Penn a non-refundable, non-assessable
option exercise fee of $20,000.

 

		3)	Within thirty (30) days of the execution of this Third Amendment, Company agrees to pay all historical
patent expenses associated with this Third Amendment, if any, that adds the Additional Dockets. These expenses include, but are
not limited to, all historically accrued patent and licensing expenses, attorney’s fees, official fees and all other charges
incident to the preparation, prosecution and maintenance of the Penn Patent Rights that were incurred and docketed by Penn relating
to the Additional Penn Dockets on or before the Effective Date of this Third Amendment.

 

		4)	This section reaffirms Company’s obligations to reimburse Penn for all documented attorney’s
fees, expenses, official fees and other charges incident to the preparation, prosecution, maintenance and licensing of Penn Patent
Rights pursuant to the terms of the Agreement, as amended.

 

    	 

    	 

    

 

EXECUTION COPY

 

		5)	Except as specifically modified or amended hereby, the Agreement, as amended by the First Amendment
and the Second Amendment, shall remain in full force and effect.

 

		6)	No provision of this Amendment may be modified or amended except expressly in a writing signed
by all parties nor shall any term be waived except expressly in a writing signed by the party charged therewith.

 

		7)	This Third Amendment may be executed in two or more counterparts, each of which shall be deemed
an original but all of which taken constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties, intending
to be legally bound, have caused this Third Amendment to be executed by their duly authorized representatives.

 

	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
	By:	/s/ Michael J. Cleare	 
	Name:	Michael J. Cleare, PhD	 
	Title:	Executive Director	 
	Date:	12/07/11	 

 

	ADVAXIS, INC.	 
	By:	/s/ John Rothman	 
	Name:	John Rothman	 
	Title:	Executive VP: Science & Operations	 
	Date:	December 2, 2011	 

 

    	2

    	 

    

 

EXECUTION COPY

  

Exhibit 1

List of Intellectual Property

 

	D751	Live, Recombinant Listeria Monocytogenes Vaccines and Production of Cytotoxic T-Cell Response

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	02/07/1994	 	08/192,857	 	 	 	CIP	 	Abandoned	 	US
	10/31/1990	 	07/606,546	 	 	 	Utility	 	Abandoned	 	US
	03/26/1993	 	08/038,356	 	 	 	CIP	 	Abandoned	 	US
	12/30/1994	 	08/366,477	 	5,830,702	 	Continuation	 	Issued	 	US

 

	H1219	Specific Immunotherapy of Cancer Using a Live Recombinant Bacterial Vaccine Vector

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	11/03/1995	 	PCT/U51995/014741	 	11/03/1995	 	PCT	 	Expired	 	WPO
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	Germany
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	Switzerland
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	Liechtenstein
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	Belgium
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	Ireland
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	France
	11/03/1995	 	95939926.2	 	0790835	 	EPOValidated	 	Issued	 	UK
	11/03/1995	 	515534/96	 	3995712	 	National Phase	 	Issued	 	Japan
	11/08/1994	 	08/336,372	 	6,051,237	 	Utility	 	Issued	 	US
	11/03/1995	 	95939926.2	 	0790835	 	National Phase	 	Issued	 	EPO
	11/03/1995	 	2,204,666	 	2,204,666	 	National Phase	 	Issued	 	Canada
	05/10/2007	 	2007-125462	 	 	 	Divisional	 	Filed	 	Japan

 

Methods and compositions for Immunotherapy
of cancer 

	03/27/2000	 	09/535,212	 	6,565,852	 	CIP	 	Issued	 	US
	05/20/2003	 	10/441,851	 	7,135,188	 	Continuation	 	Filed	 	US

 

	J1598	Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of $1(Listeria)Expressing Heterologous Antigens

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	11/13/1998	 	PCT/US1998/024357	 	 	 	PCT	 	Expired	 	WPO

 

    	3

    	 

    

 

EXECUTION COPY

 

	 	Immunogenic Compositions Comprising DAL/DAT Double-Mutant, Auxotrophic, Attenuated Strains of Listeria and their Methods of Use

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	11/13/1998	 	2,309,790	 	05083948	 	National Phase	 	Issued	 	Canada
	11/18/1997	 	08/972,902	 	6,099,848	 	Utility	 	Issued	 	US
	11/13/1998	 	14108/99	 	730296	 	National Phase	 	Issued	 	Australia
	10/07/2008	 	12/216,806	 	 	 	Continuation	 	Filed	 	US
	11/13/1998	 	98957980.0	 	1032417	 	National Phase	 	Issued	 	EPO
	11/13/1998	 	98957980.0	 	 	 	EPOValidated	 	Issued	 	France
	11/13/1998	 	98957980.0	 	698 41 437.
 3-08	 	EPOValidated	 	Issued	 	Germany
	11/13/1998	 	98957980.0	 	 	 	EPOValidated	 	Issued	 	UK

 

	 	Isolated nucleic adds comprising Listeria dal and dat genes

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	03/07/2000	 	09/520,207	 	6,504,020	 	Divisional	 	Issued	 	US
	05/01/2002	 	10/136,253	 	6,635,749	 	Divisional	 	Issued	 	US

 

	 	A Bacterial Vaccine Vector and Methods of Use Thereof

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	09/11/2003	 	10/660,194	 	7,488,487	 	Continuation	 	Issued	 	US

 

	L2134	Compositions, Methods, and Kits for Enhancing the Immunogenicity of a Bacterial Vaccine Vector

	File Date	 	Serial No.	 	Patent No.	 	App, Type	 	Status	 	Country
	01/09/2003	 	60/439,009	 	 	 	Provisional	 	Expired	 	US
	01/04/2001	 	60/259,738	 	 	 	Provisional	 	Expired	 	US
	 	 	20044204751	 	 	 	National Phase	 	Abandoned	 	Australia
	 	 	06104227 1	 	 	 	National Phase	 	Abandoned	 	Hong Kong
	01/08/2004	 	PCT/US2004/000366	 	 	 	PCT	 	Expired	 	WPO
	01/08/2004	 	04700858.6	 	 	 	EPO	 	Abandoned	 	EPO
	 	 	2,512,812	 	 	 	National Phase	 	Abandoned	 	Canada
	 	 	169553	 	 	 	National Phase	 	Abandoned	 	Israel
	01/08/2008	 	2006-500840	 	 	 	National Phase	 	Abandoned	 	Japan
	04/27/2006	 	10/541,614	 	 	 	National Phase	 	Filed	 	US

 

	02876	Compositions and Methods for Enhancing the Immunogenicity of Antigens
	 	 
	Q3610	Antibiotic Resistance Free DNA Vaccines

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	08/13/2004	 	60/601,493	 	 	 	Provisional	 	Expired	 	US
	 	 	05810446.4	 	 	 	EPO	 	Abandoned	 	EPO
	 	 	2007-525862	 	 	 	National Phase	 	Filed	 	Japan
	08/15/2005	 	2,577,270	 	 	 	National Phase	 	Abandoned	 	Canada
	08/15/2005	 	PCT/US2005/028896	 	 	 	PCT	 	Expired	 	WPO
	08/15/2005	 	2005271247	 	 	 	National Phase	 	Abandoned	 	Australia
	08/15/2005	 	11/203,408	 	 	 	Utility	 	Filed	 	US

 

    	4

    	 

    

 

EXECUTION COPY

 

	Q3614	Methods for Constructing Antibiotic Resistance Free Vaccines

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	08/15/2005	 	PCT/US2005/028895	 	 	 	PCT	 	Expired	 	WPO
	08/13/2004	 	60/601,492	 	 	 	Provisional	 	Expired	 	US
	08/15/2005	 	2005271246	 	 	 	National Phase	 	Abandoned	 	Australia
	08/15/2005	 	2,577,306	 	 	 	National Phase	 	Abandoned	 	Canada
	08/15/2005	 	2007-525861	 	 	 	National Phase	 	Filed	 	Japan
	08/15/2005	 	05808671.1	 	 	 	EPO	 	Filed	 	EPO
	08/15/2005	 	11/203,415	 	 	 	Utility	 	Filed	 	US

 

	 	Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	04/16/2007	 	11/785,249	 	 	 	CIP	 	Filed	 	US
	04/27/2007	 	11/818,965	 	 	 	CIP	 	Filed	 	US
	04/15/2008	 	08742912.2	 	 	 	National Phase	 	Filed	 	EPO
	04/15/2008	 	2010-504068	 	 	 	National Phase	 	Filed	 	Japan
	04/15/2008	 	PCT/U508/04861	 	 	 	PCT	 	Expired	 	WPO

 

	 	A technique for constructing antibiotic resistant free vaccine strains of plasmid L monocytogenes that express antigen from a high copy number

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	4/27/2007	 	60/924,033	 	 	 	Provisional	 	Expired	 	US

 

	R3702	Listeria-Based and Llo-Based Vaccines

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	 	 	2,581,331	 	 	 	National Phase	 	Abandoned	 	Canada
	09/14/2005	 	PCT/US2005/032682	 	 	 	PCT	 	Expired	 	WPO
	 	 	2007-533537	 	 	 	National Phase	 	Filed	 	Japan
	 	 	2005289957	 	 	 	National Phase	 	Abandoned	 	Australia
	11/10/2005	 	60/735,184	 	 	 	Provisional	 	Expired	 	US
	 	 	05811815.9	 	 	 	National Phase	 	Filed	 	EPO
	09/24/2004	 	10/949,667	 	7,794,729	 	CIP	 	Issued	 	US
	09/13/2005	 	11/223,945	 	7,820,180	 	CIP	 	Issued	 	US

 

	 	LLO-encoding DNA/nucleic acid vaccines and methods comprising same

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	11/13/2006	 	12/084,829	 	 	 	National Phase	 	Abandoned	 	US
	11/13/2006	 	PCT/U506/43987	 	 	 	PCT	 	Expired	 	WPO

 

    	5

    	 

    

 

EXECUTION COPY

 

	54225	Compositions and Methods for Treatment of Non-Hodgkins Lymphoma

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	05/02/2006	 	11/415,271	 	 	 	CIP	 	Filed	 	US
	05/02/2007	 	PCT/US2007/10635	 	 	 	PCT	 	Expired	 	WPO

 

	 	Compositions and Methods for Enhancing the Immunogenicity of Antigens

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	03/07/2008	 	08726578.1	 	 	 	National Phase	 	Filed	 	EPO
	03/07/2008	 	2009-552749	 	 	 	National Phase	 	Filed	 	Japan

 

	 	Compositions and Methods for Treatment of Cervical Cancer

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	03/08/2007	 	11/715,497	 	 	 	CIP	 	Filed	 	US
	03/07/2008	 	PCT/US2008/03067	 	 	 	PCT	 	Expired	 	US

 

	S4243	Methods and Compositions for Treating IgE-Mediated Diseases

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	08/06/2007	 	07811120.0	 	 	 	National Phase	 	Filed	 	EPO
	08/06/2007	 	2009-523812	 	 	 	National Phase	 	Abandoned	 	Japan
	08/04/2006	 	60/835,420	 	 	 	Provisional	 	Expired	 	US
	08/06/2007	 	PCT/US2007/017479	 	 	 	PCT	 	Expired	 	WPO
	08/06/2007	 	11/882,782	 	 	 	Utility	 	Abandoned	 	US

 

	T4531	Detoxified Non-Hemolytic LLO (by Site-Direct Mutagenesis) as a Protein Carrier for Antigens to Enhance Immunogenicity

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	06/23/2008	 	12/213,696	 	 	 	CIP	 	Filed	 	US
	06/22/2009	 	PCT/US09/413085	 	 	 	PCT	 	Flied	 	WPO

 

	U4810	Compositions Comprising Angiogenic Factors and Methods of use Thereof

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	03/04/2009	 	61/157,367	 	 	 	Provisional	 	Filed	 	US
	03/04/2010	 	PCT/US10/26257	 	 	 	PCT	 	Filed	 	WPO

 

	W5279	ISG 15 is a novel tumor antigen that can be used as a target for immunotherapy

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	4/19/10	 	61/325473	 	 	 	Provisional	 	Filed	 	US
	TBD	 	TBD	 	 	 	Utility	 	In Prep	 	US

 

    	6

    	 

    

 

EXECUTION COPY

 

	X5631	The use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals

	File Date	 	Serial No.	 	Patent No.	 	App Type	 	Status	 	Country
	10/01/2010	 	61/388,822	 	 	 	Provisional	 	Filed	 	US
	11/03/2010	 	61/409,730	 	 	 	Provisional	 	Filed	 	US

 

    	7Exhibit 10.1

 

JOINT VENTURE AGREEMENT

 

Diamond V Associates, Inc.

 

 

THIS JOINT VENTURE AGREEMENT (“Agreement”),
made and entered into as of this 3rd day of June, 2012 by and between Green Technology Solutions, Inc. (hereafter referred
to as “GTSO”), whose address is 2880 Zanker Road, Suite 203, San Jose, CA 95134 and Diamond V Associates, Inc. (hereafter
referred to as “DVA”) whose address is P.O. Box 852, Girdwood, Alaska.

 

ARTICLE I: GENERAL PROVISIONS

 

1.01 Business Purpose. The business
of the Joint Venture shall be to fund the research, planning and development of tungsten and other rare earths and precious metals
in North America and Africa.

 

1.02 Term of the Agreement. This
Joint Venture shall commence on the date first above written and shall continue in existence until terminated, liquidated, or dissolved
by law or as hereinafter provided.

 

ARTICLE II: GENERAL DEFINITIONS

 

The following comprise the general definitions
of terms utilized in this Agreement:

 

2.01 Affiliate. An Affiliate of
an entity is a person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common
control of such entity.

 

2.02 Capital Contribution(s). The
capital contribution to the Joint Venture actually made by the parties, including property, cash and any additional capital contributions
made.

 

2.03 Profits and Losses. Any income
or loss of the Joint Venture for federal income tax purposes determined by the Joint Venture’s fiscal year, including, without
limitation, each item of Joint Venture income, gain, loss or deduction.

 

ARTICLE III: OBLIGATIONS OF THE JOINT VENTURERS

 

3.01 Obligations. The Parties to
this Joint Venture shall jointly be responsible for all operations and decisions of the Joint Venture and will be compensated for
providing various services as mutually agreed in a Joint Venture Operating Agreement to be developed subsequent to the signing
of this Agreement. It is the intent of the Parties to this Joint Venture that the Joint Venture shall be separate and distinct
from the corporate business activities of the respective Parties that operate outside the definition of Purpose set forth in this
Agreement.

 

ARTICLE IV: ALLOCATIONS

 

4.01 Profits and Losses. Commencing
on the date hereof and ending on the termination of the business of the Joint Venture, all profits, losses and other allocations
to the Joint Venture shall be allocated as follows at the conclusion of each fiscal year: GTSO - 50%; DVA - 50%

 

    	 

    	 

    
 

ARTICLE V: RIGHTS AND DUTIES OF THE JOINT
VENTURERS

 

5.01 Business of the Joint Venture.
The Joint Venture parties, by and through their voting representatives, shall have full, exclusive and complete authority and discretion
in the management and control of the business of the Joint Venture for the purposes herein stated and shall make all decisions
affecting the business of the Joint Venture.

 

ARTICLE VI: AGREEMENTS WITH THIRD PARTIES
AND WITH AFFILIATES OF THE JOINT VENTURERS

 

6.01 Validity of Transactions. Affiliates
of the parties to this Agreement may be engaged to perform services for the Joint Venture. The validity of any transaction, agreement
or payment involving the Joint Venture and any Affiliates of the parties to this Agreement otherwise permitted by the terms of
this Agreement shall not be affected by reason of the relationship between them and such Affiliates or the approval of said transactions,
agreement or payment.

 

6.02 Other Business of the Parties to
this Agreement. The parties to this Agreement and their respective Affiliates may have interests in businesses other than the
Joint Venture business. The Joint Venture shall not have the right to the income or proceeds derived from such other business interests
and, even if they are competitive with the Partnership business, such business interests shall not be deemed wrongful or improper.

 

6.03 Assignment of Interest. GTSO
shall have the right to sell or assign its interest in this Joint Venture without restriction or approval from any other Joint
Venture Partner.

 

ARTICLE VII: FUNDING
FOR THE JOINT VENTURE

 

7.01 Funding. GTSO shall contribute
the working capital and DVA shall contribute its knowledge, excavation and development skills to identify prospects and maintain
operations for mineral extraction as a consideration for this Joint Venture. Upon execution of this Agreement, GTSO shall contribute
$2,000.00 per month to the joint venture, so that DVA can coordinate and develop mining prospects and operations. Should more work
be needed to be performed by DVA other than originally anticipated, the monthly payment will be renegotiated. Each project that
is funded that was sourced by DVA, GTSO and DVA shall negotiate a finders fee. All projects shall be approved and funded by agreement
of the parties.

 

ARTICLE VIII: INDEMNIFICATION OF THE JOINT
VENTURERS

 

8.01 Indemnification. The parties
to this Agreement shall have no liability to the other for any loss suffered which arises out of any action or inaction if, in
good faith, it is determined that such course of conduct was in the best interests of the Joint Venture and such course of conduct
did not constitute negligence or misconduct. The parties to this Agreement shall each be indemnified by the other against losses,
judgments, liabilities, expenses and amounts paid in settlement of any claims sustained by it in connection with the Joint Venture.

 

ARTICLE IX: DISSOLUTION

 

9.01 Events of the Joint Ventures.
The Joint Venture shall be dissolved upon the happening of any of the following events: (a) The adjudication of bankruptcy, filing
of a petition pursuant to a Chapter of the Federal Bankruptcy Act, withdrawal, removal or insolvency of either of the parties.
(b) The sale or other disposition, not including an exchange of all, or substantially all, of the Joint Venture assets. (c) Mutual
agreement of the parties. (d) A 30 day notice from one party to the other terminating the Joint Venture. The parties shall do a
final accounting prior to the formal termination of the Joint Venture.

 

9.02 Failure to Act in Good Faith.
GTSO has the right to cease capital contributions under this Agreement if in its sole discretion DVA is not acting in good faith
per its milestone and operational obligations under the proposed Joint Venture Operating Agreement.

 

9.03 Dissolution Agreement. Should
dissolution occur, the parties agree to negotiate and enter into an agreement regarding dissolution of the Joint Venture operations,
products and markets.

 

    	 

    	 

    
 

ARTICLE X: MISCELLANEOUS PROVISIONS

 

10.01 Books and Records. DVA and
GTSO shall keep adequate books and records at its place of business, setting forth a true and accurate account of all business
transactions arising out of and in connection with the conduct of the Joint Venture.

 

10.02 Validity. In the event that
any provision of this Agreement shall be held to be invalid, the same shall not affect in any respect whatsoever the validity of
the remainder of this Agreement.

 

10.03 Integrated Agreement. This
Agreement constitutes the entire understanding and agreement among the parties hereto with respect to the subject matter hereof,
and there are no agreements, understandings, restrictions or warranties among the parties other than those set forth herein provided
for.

 

10.04 Headings. The headings, titles
and subtitles used in this Agreement are for ease of reference only and shall not control or affect the meaning or construction
of any provision hereof.

 

10.05 Notices. Except as may be
otherwise specifically provided in this Agreement, all notices required or permitted hereunder shall be in writing and shall be
deemed to be delivered when deposited in the United States mail, postage prepaid, certified or registered mail, return receipt
requested, addressed to the parties at their respective addresses set forth in this Agreement or at such other addresses as may
be subsequently specified by written notice.

 

10.06 Applicable Law and Venue.
This Agreement shall be construed and enforced under the laws of the State of Texas.

 

10.07 Other Instruments. The parties
hereto covenant and agree that they will execute each such other and further instruments and documents as are or may become reasonably
necessary or convenient to effectuate and carry out the purposes of this Agreement.

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above written.

 

Signed, sealed and delivered by:

 

	DIAMOND V ASSOCIATES, INC.	 	 	 	 
	An Alaska Corporation	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By:	/s/ W. Kirk Bastian	 	 	June 8, 2012	 
	 	W. KIRK BASTIAN, CEO	 	 	Date	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	GREEN TECHNOLOGY SOLUTIONS, INC.	 	 	 	 
	A California Corporation	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By:	/s/ Paul Watson	 	 	June 8, 2012	 
	 	PAUL WATSON, CEO	 	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]